Mississippi’s drug laws treat 7‑Hydroxymitragynine as an illegal substance; under the 2026 revision of the state’s controlled‑substance schedule, it is listed as a Schedule I analog of mitragynine. Anyone possessing, distributing, or manufacturing the compound faces criminal prosecution, even if it is derived from a plant source. The answer is a clear no – 7‑Hydroxymitragynine is not legal in Mississippi as of 2026.
Statutory Framework
Mississippi’s controlled‑substance statutes were overhauled in 2024 and again in 2026 to address emerging psychoactive compounds. Mississippi Code § 41‑29‑4 defines “analog” as any substance substantially similar in chemical structure or effect to a listed drug. In 2026, the legislature expressly added mitragynine and its metabolites, including 7‑Hydroxymitragynine, to Schedule I, referencing the U.S. DEA’s temporary scheduling order of 2023. The statute’s language makes no distinction between natural extracts and synthetic isolates; both fall under the prohibition.
How 7‑Hydroxymitragynine Is Classified
Schedule I in Mississippi denotes substances with a high potential for abuse and no accepted medical use. The classification aligns Mississippi with federal policy, which placed 7‑Hydroxymitragynine under the Temporary Controlled Substance Order (2023) before it was permanently scheduled in 2025. The state law’s “substantially similar” clause captures any derivative, preparation, or mixture containing the alkaloid, even at trace levels.
Enforcement and Penalties
Law enforcement agencies apply the same penalties to 7‑Hydroxymitragynine as they do to other Schedule I drugs. Possession of less than 1 gram is a felony punishable by up to five years in prison and a fine of up to $5,000 (Miss. Code § 41‑29‑13). Trafficking or manufacturing carries a minimum sentence of ten years, with fines exceeding $25,000. Courts frequently use expert testimony to establish chemical similarity, making convictions more likely even when the substance is embedded in herbal products marketed as “kratom extracts.”
Implications for Researchers and Patients
Academic and clinical researchers must obtain a Schedule I research registration from the Mississippi Department of Health, a process that involves extensive background checks and secure storage protocols. The registration fee and administrative burden have discouraged many institutions from studying the compound’s therapeutic potential. Patients seeking pain relief through kratom‑derived products are at legal risk, as the presence of 7‑Hydroxymitragynine—whether intentional or accidental—can trigger criminal liability.
Future Legislative Trends
Legislators continue to monitor the opioid crisis and the rise of novel analgesics. A 2026 bipartisan bill proposes a “medical exception” for certain kratom derivatives, but it has not yet advanced out of committee. Until such reforms are enacted, the current prohibition remains enforceable.
Frequently Asked Questions
What specific statute makes 7‑Hydroxymitragynine illegal in Mississippi?
Mississippi Code § 41‑29‑4, as amended in 2026, classifies 7‑Hydroxymitragynine an analog of mitragynine and places it in Schedule I.
Does the law differentiate between synthetic and plant‑derived 7‑Hydroxymitragynine?
No. The “analog” provision covers any material containing the compound, regardless of source.
Can a researcher obtain a permit to study 7‑Hydroxymitragynine in Mississippi?
Yes, but a Schedule I research registration is required, involving a rigorous application and secure laboratory standards.
Are there any medical exemptions for the compound?
As of 2026, Mississippi has no medical exemption for 7‑Hydroxymitragynine; any use is considered unlawful.
How does Mississippi’s stance compare to federal law?
Both federal and state law treat the compound as a Schedule I substance, reflecting a consistent prohibition across jurisdictions